The transaction has been unanimously approved by the Board of Directors ... The Anaren, Inc. logo is available at About AML: AML is a designer, manufacturer, and marketer of microelectronic ...

A considerable proportion of the recently approved and pipeline AML treatments are mutationally targeted, and despite their smaller target patient populations, are anticipated to contribute ...

Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with relapsed or ...

Treosulfan plus fludarabine is approved for alloHSCT in patients with AML or MDS aged 1 year and older. Clinical trial results showed improved overall survival with treosulfan compared to busulfan.

"If approved, quizartinib has the potential to meaningfully advance treatment for patients with relapsed or refractory FLT3-ITD AML. Patients need more treatment options for this type of AML ...

An oral targeted therapy that can be used in patients with relapsed/refractory acute myeloid leukemia (AML) who carry a mutation in the isocitrate dehydrogenase-2 (IDH2) enzyme has been approved.

September 28, 2012 — The European Commission has approved the hypomethylating agent decitabine (Dacogen, Astex/Eisai) for acute myeloid leukemia (AML) in adults 65 years and older, Astex ...